SARS-CoV-2 B.1.1.529 (Omicron) S1+S2 trimer Protein (ECD)

Catalog# BRP1141

Lot # Check on the product label

Size 1 mg

Description

Recombinant Severe Acute Respiratory Syndrome-Corona Virus-2 B.1.1.529 (Omicron) S1+S2-ECD trimer protein with His tag at C-terminal (136.67 kDa).

Source HEK293

Purity >95% by SDS-PAGE & HPLC

Endotoxin level <1.0 EU per μg protein as determined by the LAL method.

Biological Activity

Pre-coated human ACE2 protein (hFc tag) at 2 μg/ml, it can bind with SARS-CoV-2 B.1.1.529 (Omicron) Spike RBD Protein (His Tag), the EC₅₀ is 4-10 ng/mL.

Formulation Liquid

Application

Lateral flow (rapid test)

Other applications have not been tested.

The optimal dilutions should be determined by end user.

Storage buffer

Each vial contains 0.01 M PBS (pH7.4).

Storage & Expiration

Ship at 2-8℃. Upon receipt, aliquot and store at -20℃ for long term.

Avoid repeated freeze and thaw cycles.

Background

The 2019 novel coronavirus, abbreviated as 2019-ncov, is a new strain of coronavirus discovered in the human body in 2019. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2,  angiotensin-converting enzyme 2; DPP4, dipeptidyl peptidase-4; APN, aminopeptidase N; CEACAM, carcinoembryonic antigen-related cell adhesion molecule. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations A67V, HV69-70 deletion, T95I, G142D, VYY143-145 deletion, N211 deletion, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, F817P, N856K, A892P, A899P, A942P, Q954H, N969K, L981F, K986P, V987P and furin cleavage site mutants) expressed with the bacteriophage T4 fibritin and a his tag at the C-terminal. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.529) which emerged in the South Africa.

Reference

1. World Health Organization: Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim Guidance.

2. "Pneumonia diagnosis and treatment program for novel coronavirus infection" of the National Health Commission of People’s Republic of China (Trial Version 3).